Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) have received a consensus rating of “Moderate Buy” from the five brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $10.00.

Several equities analysts have weighed in on AMRX shares. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a report on Friday, September 6th. StockNews.com upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, November 11th. Piper Sandler boosted their price objective on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Finally, Truist Financial increased their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, October 2nd.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, SVP Jason B. Daly sold 43,657 shares of the business’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $8.61, for a total value of $375,886.77. Following the sale, the senior vice president now owns 13,665 shares in the company, valued at approximately $117,655.65. The trade was a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 26.56% of the company’s stock.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in AMRX. Profund Advisors LLC lifted its holdings in shares of Amneal Pharmaceuticals by 8.1% in the 2nd quarter. Profund Advisors LLC now owns 22,522 shares of the company’s stock valued at $143,000 after acquiring an additional 1,680 shares during the last quarter. Rothschild Investment LLC bought a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter valued at approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Amneal Pharmaceuticals by 13.3% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company’s stock valued at $222,000 after purchasing an additional 4,115 shares during the last quarter. Franklin Resources Inc. boosted its holdings in shares of Amneal Pharmaceuticals by 4.9% in the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock worth $778,000 after purchasing an additional 4,178 shares during the period. Finally, Gladius Capital Management LP bought a new position in shares of Amneal Pharmaceuticals during the 3rd quarter valued at approximately $37,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Stock Down 1.1 %

NASDAQ AMRX opened at $7.83 on Friday. Amneal Pharmaceuticals has a 52 week low of $4.74 and a 52 week high of $9.48. The company has a market capitalization of $2.43 billion, a P/E ratio of -11.51 and a beta of 1.12. The stock’s 50-day moving average price is $8.49 and its 200-day moving average price is $7.90.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.